These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28194032)

  • 1. Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
    Mizrachi A; Shamay Y; Shah J; Brook S; Soong J; Rajasekhar VK; Humm JL; Healey JH; Powell SN; Baselga J; Heller DA; Haimovitz-Friedman A; Scaltriti M
    Nat Commun; 2017 Feb; 8():14292. PubMed ID: 28194032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
    Elkabets M; Pazarentzos E; Juric D; Sheng Q; Pelossof RA; Brook S; Benzaken AO; Rodon J; Morse N; Yan JJ; Liu M; Das R; Chen Y; Tam A; Wang H; Liang J; Gurski JM; Kerr DA; Rosell R; Teixidó C; Huang A; Ghossein RA; Rosen N; Bivona TG; Scaltriti M; Baselga J
    Cancer Cell; 2015 Apr; 27(4):533-46. PubMed ID: 25873175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.
    Ruicci KM; Meens J; Sun RX; Rizzo G; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Boutros PC; Ailles L; Nichols AC
    Int J Cancer; 2019 Oct; 145(8):2100-2106. PubMed ID: 30468243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer.
    Xu YC; Wang X; Chen Y; Chen SM; Yang XY; Sun YM; Geng MY; Ding J; Meng LH
    Theranostics; 2017; 7(4):974-986. PubMed ID: 28382169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
    Keam B; Kim S; Ahn YO; Kim TM; Lee SH; Kim DW; Heo DS
    Anticancer Res; 2015 Jan; 35(1):175-82. PubMed ID: 25550549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
    Fritsch C; Huang A; Chatenay-Rivauday C; Schnell C; Reddy A; Liu M; Kauffmann A; Guthy D; Erdmann D; De Pover A; Furet P; Gao H; Ferretti S; Wang Y; Trappe J; Brachmann SM; Maira SM; Wilson C; Boehm M; Garcia-Echeverria C; Chene P; Wiesmann M; Cozens R; Lehar J; Schlegel R; Caravatti G; Hofmann F; Sellers WR
    Mol Cancer Ther; 2014 May; 13(5):1117-29. PubMed ID: 24608574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
    Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
    Bhatia S; Griego A; Lennon S; Oweida A; Sharma J; Rohmer C; Uyanga N; Bukkapatnam S; Van Court B; Raben D; Young C; Heasley L; Karam SD
    Mol Cancer Ther; 2018 Sep; 17(9):2049-2059. PubMed ID: 29970482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
    Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
    PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
    Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
    Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-silico prediction of potential inhibitors against phosphatidylinositol 3-kinase catalytic subunit alpha involved in head and neck squamous cell carcinomas.
    Madhukar G; Subbarao N
    J Biomol Struct Dyn; 2022 Jul; 40(10):4697-4712. PubMed ID: 33356909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy.
    Chuang FC; Wang CC; Chen JH; Hwang TZ; Yeh SA; Su YC
    PLoS One; 2021; 16(1):e0245715. PubMed ID: 33471836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer.
    Costa C; Ebi H; Martini M; Beausoleil SA; Faber AC; Jakubik CT; Huang A; Wang Y; Nishtala M; Hall B; Rikova K; Zhao J; Hirsch E; Benes CH; Engelman JA
    Cancer Cell; 2015 Jan; 27(1):97-108. PubMed ID: 25544637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-tumour activity of rLj-RGD4, an RGD toxin protein from Lampetra japonica, on human laryngeal squamous carcinoma Hep-2 cells in nude mice.
    Shao F; Lv M; Zheng Y; Jiang J; Wang Y; Lv L; Wang J
    Biochimie; 2015 Dec; 119():183-91. PubMed ID: 26549486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
    Jin N; Keam B; Cho J; Lee MJ; Kim HR; Torosyan H; Jura N; Ng PK; Mills GB; Li H; Zeng Y; Barbash Z; Tarcic G; Kang H; Bauman JE; Kim MO; VanLandingham NK; Swaney DL; Krogan NJ; Johnson DE; Grandis JR
    J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
    Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM
    JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.